A Study to Assess the Efficacy and Safety of GIA632 Across a Range of Doses in Participants With Moderate to Severe Cutaneous Lichen Planus

Last Update: Aug 26, 2026

A Phase IIb Multicenter, Randomized, Double-blind, Placebo-controlled, Dose-range Study to Assess the Efficacy and Safety of GIA632 in Participants With Moderate to Severe Cutaneous Lichen Planus, Followed by an Extension Period

ClinicalTrials.gov Identifier:

NCT07775924

Novartis Reference Number:CGIA632C12201

See if you Pre-qualify

All compounds are either investigational or being studied for (a) new use(s). Efficacy and safety have not been established. There is no guarantee that they will become commercially available for the use(s) under investigation.

Study Description

This study will evaluate the safety and efficacy of GIA632 in participants with moderate to severe cutaneous lichen planus (cLP). The main purpose of this study is to investigate the safety and efficacy of GIA632 in participants with moderate to severe cutaneous lichen planus (cLP) across a range of dosing regimens and to identify the optimal dosing regimen to be promoted into the confirmatory Phase 3 program.

This study consists of a screening period (up to 4 weeks), a core treatment period (16 weeks double-blind), an extension period (52 weeks), and a safety follow-up period (12 weeks).

Condition

Cutaneous Lichen Planus

Phase

Phase2

Overall Status

Recruiting

Number of Participants

259

Start Date

Sep 10, 2026

Completion Date

Feb 13, 2030

Gender

All

Age(s)

18 Years - 99 Years (Adult, Older Adult)

Interventions

Drug

GIA632

GIA632 administered according to the assigned study treatment regimen.

Drug

Placebo

Matching placebo

Eligibility Criteria

Key Inclusion Criteria:

* Male or female (as assigned at birth) participants ≥ 18 years of age at the time of screening.
* Individuals with a diagnosis of cLP, confirmed
* histologically by a skin biopsy (either historically within 1 year prior to screening or at screening if historical one not available), and
* by physical examination by the investigator at screening.
* Moderate to severe cLP
* Two or more body regions affected (any two or more of the following: head and neck, trunk, upper extremities including hands, lower extremities including feet).
* Diagnosis of cLP inadequately controlled by at least one topical treatment for at least 3 months (either via continuous use or burst and taper regimen), or such treatment being considered not advisable, as per investigator judgement, assessed at screening.

Topical treatment includes, but is not limited to, topical corticosteroids, topical calcineurin inhibitors, topical cholecalciferol analogues, topical PDE4 inhibitors, topical JAK inhibitors, and topical aryl hydrocarbon receptor agonists.

Key Exclusion Criteria:

* Individuals unable or unwilling to follow the study procedures, handle the electronic diary (eDiary), and/or to complete the study-related questionnaires.
* Diagnosis of drug-induced lichen planus (lichenoid drug eruption) or lichen planus pigmentosus.
* Presence of skin conditions that may interfere with study assessments, including histologic findings in the biopsy, as assessed at screening and baseline.
* Previous exposure to biologic drugs directly targeting IL-15 or any subunit of the IL-15 receptor.
* Use of prohibited medication and treatments.

Other protocol-defined inclusion/exclusion criteria may apply.